skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Metabolism of L-(guanidinooxy-/sup 14/C)canavanine in the rat

Journal Article · · Toxicol. Appl. Pharmacol.; (United States)

The metabolism of L-canavanine, a nonprotein amino acid with significant antitumor effects, was investigated. L-Canavanine, provided at 2.0 g/kg, was supplemented with 5 microCi of L-(guanidinooxy-/sup 14/C)canavanine (58 microCi/mumol) and administered iv, sc, or orally to female Sprague-Dawley rats weighing approximately 200 g. /sup 14/C recovery in the urine at 24 hr was 83, 68, or 61%, respectively, of the administered dose. Another 5-8% of the /sup 14/C was expired as /sup 14/CO/sub 2/. The gastrointestinal tract contained 21% of orally administered /sup 14/C. Serum, feces, tissues, and de novo synthesized proteins only accounted for a few percent of the original dose by any administrative route. Analysis of the /sup 14/C-containing urinary metabolites revealed that (/sup 14/C) urea accounted for 88% of the urinary radioactivity for an iv injection, 75% for sc administration, and 50% following an oral dose. By all routes of administration, (/sup 14/C)guanidine represented 5% of the radioactivity in the urine and (/sup 14/C)guanidinoacetic acid accounted for 2%. Serum and urine amino acid analysis showed a markedly elevated ornithine level. Basic amino acids such as histidine, lysine, and arginine were also higher in the urine. Plasma ammonia levels were determined following oral canavanine doses of 1.0, 2.0, and 4.0 g/kg. A rapid but transient elevation in plasma ammonia was observed only at the 4.0 g/kg dose. This indicates that elevated plasma ammonia is not a likely cause of canavanine toxicity at the drug concentrations used in this study.

Research Organization:
Univ. of Kentucky, Lexington
OSTI ID:
5411856
Journal Information:
Toxicol. Appl. Pharmacol.; (United States), Vol. 91:3
Country of Publication:
United States
Language:
English